Cannabinoids and B cells: Emerging targets for treating progressive multiple sclerosis

Multiple Sclerosis Journal

Volumn 17, Issue 3, 2011, Pages 259-261

  Giovannoni, Gavin ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID RECEPTOR; IMMUNOGLOBULIN M; OLIGOCLONAL BAND;

B LYMPHOCYTE; DISEASE COURSE; DISEASE SEVERITY; EDITORIAL; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; PROGNOSIS;

EID: 79953198285     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458511399799     Document Type: Editorial

References (23)

1. Hensiek AE, Seaman SR, Barcellos LF, et al. Familial effects on the clinical course of multiple sclerosis. Neurology 2007 ; 68: 376-383. (Pubitemid 46184215)
2. DeLuca GC, Ramagopalan SV, Herrera BM, et al. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Natl Acad Sci U S A 2007 ; 104: 20896-20901.
3. Stankovich J., Butzkueven H., Marriott M., et al. HLA-DRB1 associations with disease susceptibility and clinical course in Australians with multiple sclerosis. Tissue Antigens 2009 ; 74: 17-21.
4. Jensen CJ, Stankovich J., Van der Walt A., et al. Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients. PLoS ONE 2010 ; 5: e10003.
5. Rossi S., Buttari F., Studer V., et al. The (AAT)n repeat of the cannabinoid CB1 receptor gene influences disease progression in relapsing multiple sclerosis. Mult Scler 2011.
6. Jackson SJ, Diemel LT, Pryce G. and Baker D. Cannabinoids and neuroprotection in CNS inflammatory disease. J Neurol Sci 2005 ; 233: 21-25. (Pubitemid 40804812)
7. Pryce G., Ahmed Z., Hankey DJ, et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003 ; 126: 2191-2202. (Pubitemid 37432364)
8. Peninsular Medical School. Cannabinoid Use in Progressive Inflammatory Brain Disease. Plymouth: Peninsula Medical School, 2010.
9. Magliozzi R., Howell O., Vora A., et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007 ; 130: 1089-1104. (Pubitemid 47355604)
10. Prineas JW Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord. Science 1979 ; 203: 1123-1125. (Pubitemid 9148091)
11. Wolinsky JS, Narayana PA, O'Connor P., et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007 ; 61: 14-24. (Pubitemid 46214240)
12. Joseph FG, Hirst CL, Pickersgill TP, Ben-Shlomo Y., Robertson NP and Scolding NJ CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients. J Neurol Neurosurg Psychiatry 2009 ; 80: 292-296.
13. Sola P., Mandrioli J., Simone AM, et al. Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM. Mult Scler 2011.
14. Stauch C., Reiber H., Rauchenzauner M., et al. Intrathecal IgM synthesis in pediatric MS is not a negative prognostic marker of disease progression: Quantitative versus qualitative IgM analysis. Mult Scler 2011.
15. Krupp LB, Banwell B. and Tenembaum S. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007 ; 68: S7 - S12.
16. Zhao C., Li WW and Franklin RJ Differences in the early inflammatory responses to toxin-induced demyelination are associated with the age-related decline in CNS remyelination. Neurobiol Aging 2006 ; 27: 1298-1307. (Pubitemid 44067300)
17. Khademi M., Kockum I., Andersson ML, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler 2011.
18. Ruet A., Deloire MS, Ouallet JC, Molinier S. and Brochet B. Predictive factors for multiple sclerosis in patients with clinically isolated spinal cord syndrome. Mult Scler 2011.
19. Hauser S., Waubant E., Arnold D., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008 ; 358: 676-688. (Pubitemid 351240747)
20. Kappos L., O'Connor P., Bar-Or A., Li D., Barkhof F., Yin M., et al. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis: results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis 2010 ; 16: S7 - S39. (abstract 114 ).
21. Soelberg Sorensen P., Havrdova E., Lisby S., Graff O. and Shackelford S. Magnetic resonance imaging (MRI) efficacy of ofatumumab in relapsing-remitting multiple sclerosis (RRMS) - 24-week results of a phase II study. Multiple Sclerosis 2010 ; 16: S7 - S39. (abstract 136 ).
22. Hawker K., O'Connor P., Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009 ; 66: 460-471.
23. clinicaltrials.gov. Double blind combination of rituximab by intravenous and intrathecal injection versus placebo in patients with low-inflammatory secondary progressive multiple sclerosis (RIVITaLISe). Bethesda, MD: NIH, 2010.